Last reviewed · How we verify
famitinib po
At a glance
| Generic name | famitinib po |
|---|---|
| Sponsor | Jiangsu HengRui Medicine Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Famitinib Combined With SHR-A1811, Versus SHR-A1811 for CDK4/6 Inhibitors-resistent Advanced HR+/HER2- Breast Cancer With SNF4 Subtype (PHASE3)
- A Randomized, Open-label, Double-cohort Study of Fluzoparib Combined With Famitinib Malate or SHR-1701 for Neoadjuvant Therapy in Patients With Advanced Ovarian Cancer (PHASE2)
- Adebrelimab Combined With Famitinib and Irinotecan in Advanced Gastric Cancer After Failure of First-Line Therapy (PHASE2)
- A Non-interventional Registration Study of Monotherapy or Combination Regimens Based on Camrelizumab or Famitinib for the Treatment of Cervical Cancer
- A Prospective, Randomized, Parallel Trial of Famitinib Malate at Different Doses Combined With Camrelizumab for the Treatment of Recurrent and Metastatic Cervical Cancer (PHASE2)
- SNF Platform Study of HR+/ HER2-advanced Breast Cancer (PHASE2)
- A Study of Adebrelimab Combined With Famitinib and Chemotherapy in the Treatment of ES-SCLC. (PHASE2)
- An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC. (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- famitinib po CI brief — competitive landscape report
- famitinib po updates RSS · CI watch RSS
- Jiangsu HengRui Medicine Co., Ltd. portfolio CI